V Nekljudova
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, Furlanetto J, Zahm D, Hanusch C, GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022
09.08.2022Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
09.08.2022Ann Oncol 2022
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober Jens, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, GBG and AGO-B
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
01.08.2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
01.08.2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
Deuker J, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C, Meinerz W, Grasshoff S, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372.
15.09.2014Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
15.09.2014Ann Oncol 2014; 25:2363-2372
Deuker J-U, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D-M, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H-U, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C-H, Meinerz W, Grasshoff S-T, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C-C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J-U, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J U, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
17.10.2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
17.10.2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators